Drug discovery biotech firm Chemotargets and the Centre for Genomic Regulation (CRG) have signed a strategic agreement to accelerate the development of new targeted therapies that respond to unmet clinical...
Read More
This week Chemotargets announces the launch of CLARITY PV, a new product for translational safety and pharmacovigilance professionals. Barcelona, July 5th, 2021. Chemotargets launches CLARITY PV, a new web-based platform…
The Innovative SME Seal, valid for three years, recognizes the high level of innovation in the projects, products and services of Chemotargets. Barcelona, June 1st, 2021. Chemotargets has been awarded…
In less than 12 months, the collaboration between Chemotargets and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of neurodegenerative disease. Chemotargets employed its proprietary AI-driven…
With the new incorporation, the company consolidates its transition from a software business to an AI-driven biotech company. Barcelona, 6 October 2020 – Chemotargets, a global leader in predictive analytics…
This public-private partnership will establish a framework for collaboration that promotes the creation of synergies between both institutions. Chemotargets has entered into a strategic alliance with the IMIM Hospital del…
The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has licensed the Chemotargets CLARITY® platform for predicting unknown secondary targets for new molecules of pharmaceutical interest….
GENESIS Biomed and CREA Inversión will advise in the funding, which will allow the company to expand its activity in the discovery of new drugs. Barcelona, 14 April 2020 –…
PS: SOT conference has been canceled due to the global situation regarding COVID-19 Chemotargets will participate at the Society of Toxicology Annual meeting (SOT2020) in Anaheim, California (US), March 15-19,…
Updates on data and models, and a new explorer module to navigate by scaffolds and molecules related data, the MedChem Explorer. This month, we are pleased to announce the launch…
